

UPMC Presbyterian Shadyside Automated Testing Laboratories
 Department of Pathology
 2022 Reference Ranges

| Test | Reference Range | Units |
|--|---|---------------------------|
| Serum/Plasma | | |
| AKI Risk Score (Acute Kidney Index) | Less than 0.3 | No units |
| Albumin | 0 D: 2.9-5.5 1 M: 3.8-5.4 15Y: 3.4-5.0 | g/dL |
| Alkaline Phosphatase | 0 D: less than 310 1 M: less than 360 1 Y: less than 290 10Y: less than 400 15Y: 38-126 | IU/L |
| ALT (Alanine Aminotransferase) | Male: 17-63 Female: 14-54 | IU/L |
| Ammonia | 1M to 14 Y: 12-38 15Y: 9-33 | µmol/L |
| AST(Aspartate Aminotransferase) | 15-41 | IU/L |
| Amylase | Less than 65 | IU/L |
| Anion Gap | 7-15 | mmol/L |
| Bilirubin, Direct | 0.1 – 0.5 | mg/dL |
| Bilirubin, Total | 0D: 1-12 1M: 0.2-1.3 15Y: 0.3-1.5 | mg/dL |
| BUN(Blood Urea Nitrogen) | 0D: 6-18 15Y: 8-26 | mg/dL |
| Creatinine | 0D: 0.1 - 0.6 10Y: 0.2 - 1.1 15Y: 0.5-1.4 | mg/dL |
| Calcium | 0D: 7-12 1M: 8.8-10.8 15Y: 8.4-10.2 | mg/dL |
| Chloride | 98-107 | mmol/L |
| eGFR | < 60 can indicate chronic kidney disease <15 can indicate chronic kidney failure | mL/min/1.73m ² |
| CO ₂ (Carbon Dioxide) | 21-31 | mmol/L |
| Covid 19 Antibody | Non-Reactive-This sample does not contain anti-SARV-Co V -2 IgG antibodies | |
| | Equivocal-Anti SARS-COV-2 IgG antibody status cannot be determined. | |
| | Reactive-This sample likely contains anti-SARS-CoV-2 IgG antibodies | |
| Glucose | 70-99 - Fasting Less than 1M: 40-99 Random 70-139 | mg/dL |
| Glucose Tolerance, Gestational 50 g Screen | < 135 cutoff | mg/dL |

| Test | Reference Range | Units |
|--|---|-------|
| Glucose Tolerance, Gestational 100g 3 Hr | Fasting: 65-94 | mg/dL |
| | 1 hr: <180 | mg/dL |
| | 2 hr: <150 | mg/dL |
| | 3 hr: <140 | mg/dL |
| Glucose Tolerance, 75 g, 2 hr | Fasting:<100 | mg/dL |
| | 2 hr: <140 | mg/dL |
| Magnesium | OD: 1.2-2.6 7D: 1.6-2.6 2Y: 1.6-2.2 15Y: 1.6-2.3 | mg/dL |
| Phosphorus | 0 – 14D: 5.4 – 10.4 15D – 11M: 4.5 – 8.2 1Y – 4 Y: 4.2 – 6.7 5Y – 12Y: 3.9 – 5.8 13Y – 15Y: Female: 3.0 – 5.8; Male: 3.3 -6.1 16Y – 18Y: 3.0 - 4.8 19Y: 2.5 – 4.6 | mg/dL |

| Test | Reference Range | Units |
|------------------------------------|--|--------|
| Serum/Plasma | | |
| Potassium | OD: 3.7-5.9 1M: 4.1-5.3 1Y: 3.4-4.7 15Y: 3.5-5.0 | mmol/L |
| Sodium | 136-146 | mmol/L |
| Uric Acid | OD: 2.0-5.5 15Y: 2.5-7.5 17Y: 2.5-6.2 35Y: 2.5-7.0 45Y: 2.5-7.5 | mg/dL |
| GTP (gamma glutamyl transferase) | Male - OD: less than 121 1Y: less than 45 15Y: less than or equal to 65 Female - OD: less than 121 1Y: 45 15Y: less than or equal to 40 | IU/L |
| Total Protein | OD: 4.4-7.6 1M: 5.1-7.3 1Y: 6.0-8.0 15Y: 6.3-7.7 | g/dL |
| Lipase | 15-70 | U/L |
| Total CPK (creatine phosphokinase) | Less than or equal to 200 | IU/L |
| CK-MB | 0-5 | ng/mL |
| Lactate (plasma) | 0.5-2.2 | mmol/L |
| LDH (lactate dehydrogenase) | OD: less than 450 1M: less than 250 1Y: less than 171 | IU/L |
| Iron | Male: 45-182 Female: 28-170 | ug/dL |
| Transferrin | 202-336 | mg/dL |
| TIBC | 250-420 | ug/dL |
| Ferritin | 10-282 | ng/mL |
| Folate | Greater than 5.0 | ng/mL |
| RBC Folate | 293-809 | ng/mL |
| Vitamin B12 | 211-911 | pg/mL |
| high-sensitivity Troponin I | Normal: less than 18 | ng/L |
| BNP (beta natriuretic peptide) | Less than 100 | pg/mL |
| CRP | Less than 0.75 | mg/dL |
| hs-CRP (high sensitivity CRP) | Less than 0.748 | mg/dL |
| Total βhCG | Less than 5.0 | mIU/mL |

| Test | Reference Range | Units | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--------|----------|--------|--------|------|-------|---------|------|-------|----------|------|-------|--|----------|--------|-------|------|-------|---------|------|-------|--|----------|--------|-------|------|-------|---------|------|-------|-------|
| Serum/Plasma | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| AFP (alpha fetal protein) | 0D: less than 170,000 1M: less than 400 3M: less than 30 6M: less than 20 | ng/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| CEA (carcinoembryonic antigen) | Less than 5 | ng/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| CA 15-3 (cancer antigen (breast) 15-3) | Less than 30 | U/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| CA 19-9 (cancer antigen (GI) 19-9) | Less than 33 | U/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| CA 125 (cancer antigen 125) | Less than 35 | U/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total PSA (prostate specific antigen) | 0-4.0 | ng/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Complement C3 | 79-152 | mg/dL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Complement C4 | 16-38 | mg/dL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cortisol | <p>Adults: 8am-10am: 5-21 4pm-6pm: 2-14 Post ACTH Stimulation Peak – greater than 20 Peak after IM injection – greater than 16 Child – AM: 0-7D: 2 – 15 8D- 12M: 3 – 23 1YR – 17YR: 6 – 22</p> <p>ACTH Stimulation</p> <table border="1"> <thead> <tr> <th></th> <th>Baseline</th> <th>60 Min</th> </tr> </thead> <tbody> <tr> <td>1M-12M</td> <td>3-23</td> <td>32-60</td> </tr> <tr> <td>1Y – 6Y</td> <td>6-25</td> <td>22-40</td> </tr> <tr> <td>6Y – 12Y</td> <td>3-15</td> <td>17-28</td> </tr> </tbody> </table> <p>Tanner II-III</p> <table border="1"> <thead> <tr> <th></th> <th>Baseline</th> <th>60 Min</th> </tr> </thead> <tbody> <tr> <td>Males</td> <td>4-13</td> <td>16-32</td> </tr> <tr> <td>Females</td> <td>4-16</td> <td>16-32</td> </tr> </tbody> </table> <p>Tanner IV-V</p> <table border="1"> <thead> <tr> <th></th> <th>Baseline</th> <th>60 Min</th> </tr> </thead> <tbody> <tr> <td>Males</td> <td>5-15</td> <td>18-27</td> </tr> <tr> <td>Females</td> <td>6-15</td> <td>18-35</td> </tr> </tbody> </table> | | Baseline | 60 Min | 1M-12M | 3-23 | 32-60 | 1Y – 6Y | 6-25 | 22-40 | 6Y – 12Y | 3-15 | 17-28 | | Baseline | 60 Min | Males | 4-13 | 16-32 | Females | 4-16 | 16-32 | | Baseline | 60 Min | Males | 5-15 | 18-27 | Females | 6-15 | 18-35 | µg/dL |
| | Baseline | 60 Min | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1M-12M | 3-23 | 32-60 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1Y – 6Y | 6-25 | 22-40 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6Y – 12Y | 3-15 | 17-28 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Baseline | 60 Min | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Males | 4-13 | 16-32 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Females | 4-16 | 16-32 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Baseline | 60 Min | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Males | 5-15 | 18-27 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Females | 6-15 | 18-35 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Test | Reference Range | Units |
|------------------------------------|---|--------|
| Serum/Plasma | | |
| FSH (follicle-stimulating hormone) | <p>Male 2W:1.2-5.2 19M: 0.3-1.9 10Y: 0.2-5.8 15Y: 0.8-8.2 <i>Tanner stages: I:0.3-1.9 II:0.7-4.6 III: 1.2-10.4 IV: 15-40 V 10-40</i></p> <p>Female 2W: 2.1-30.5 19M: 0.7-3.4 10Y: 0.7-7.3 15Y: 0.3-10.5 1.4-9.39 Midcycle peak: 6.2-17.2 Luteal: 1.1-9.2 Postmenopausal: 14.9-124.3 <i>Tanner stages: I:0.5-2.4 II: 1.7-4.7 III: 2.5-7.0 IV: 1.3-7.4 V:1.0-9.2</i></p> | mIU/mL |
| LH (luteinizing hormone) | <p>Male Cord blood: 0.1-2.6 2W: 4.9-10.0 19M: 0.1-1.0 10Y: 0.4-4.4 15Y: 0.7-7.2 19Y: 1.0-5.6 <i>Tanner stages: I:0.1-0.4 II:0.-4.8 III:0.6-3.7 IV:0.6-7.2 V:1.5-7.0</i></p> <p>Female Cord blood: 0.1-2.6 2W: 0.3-7.9 19M: 0.1-0.6 10Y: 0.1-4.1 15Y: 0.1-29.4 Follicular phase: 1.7-15.0 Midcycle peak: 21.9-56.6 Luteal phase: 0.6-16.3 Postmenopausal: 9.0-52.3 <i>Tanner stages:I:0.1-0.2 II:0.3-4.1 III:0.2-4.1 IV:0.7-15.0 V:0.3-29.4</i></p> | mIU/mL |
| Acetone | Negative | N/A |
| Estradiol | <p>Male: 20-75 Female: 20-88</p> | pg/mL |
| Haptoglobin | 36-195 | mg/dL |

| Test | Reference Range | Units |
|----------------------------|--|-------|
| Serum/Plasma | | |
| Prealbumin | 0M: 7-39 1M: 8-34 6M: 12-36 1Y: 8-34 4Y: 12-30 6Y: 12-42 20Y: 18-38 | mg/dL |
| IgA (SHY) Immunoglobulin A | 0D: 0-8 1M: 2-27 4M: 4-63 7M: 15-72 13M: 15-97 25M: 15-144 37M: 15-241 5Y: 15-161 7Y: 21-195 9Y: 59-301 12Y: 401-218 14Y: 82-453 | mg/dL |
| IgG (SHY) Immunoglobulin G | 0D: 605-1374 1M: 184-641 4M: 55-765 7M: 214-1055 13M: 330-1133 25M: 505-1280 37M: 559-1116 5Y: 499-1198 7Y: 580-1256 9Y: 484-1309 12Y: 577-1322 14Y: 751-1560 | mg/dL |
| IgM (SHY) immunoglobulin M | 0D: 1-20 1M: 8-49 4M: 9-73 7M: 8-95 13M: 11-99 25M: 22-94 37M: 22-99 5Y: 17-86 7Y: 21-120 9Y: 15-103 12Y: 8-133 14Y: 40-274 | mg/dL |

| Test | Reference Range | Units |
|---------------------------------|--|----------|
| Serum/Plasma | | |
| Progesterone | Males: 0.0 – 1.2 Females: Follicular phase: 0.32–4.77 Luteal phase: 7.9–87.9 Mid Luteal: 18.0–87.9 Pregnancy: 1st trimester: 27.0–141.0 2nd trimester: 51.0–438.0 3rd trimester: 165.0–765.0 | nmol/L |
| Prolactin | Males: 0.6–19 Females: 0.6–20 | ng/mL |
| Testosterone (SHY) | Males: 10.00–42.00 Females: less than 2.8 | nmol/L |
| Thyroglobulin | 3.0-40.0 | ng/mL |
| Thyroglobulin antibody | Less than 20 | IU/mL |
| Total T3 (PUH) Triiodothyronine | Female: 0D: 0.48-1.77 1M: 0.73-2.21 1Y: 1.26-2.16 6Y: 1.10-1.95 11Y: 1.04-1.84 16Y: 1.01-1.51 18Y: 0.60-1.81 Male: 0D: 0.51-1.84 1M: 1.03-2.29 1Y: 0.93-2.13 6Y: 1.04-1.98 11Y: 0.88-1.76 16Y: 0.86-1.76 18Y: 0.60-1.81 | ng/mL |
| Total T4 (Thyroxine) | 0D: 1.0-38.9 5D: 3.0-20.0 14D: 1.7-9.1 147D: 0.8–8.2 25M: 0.7–5.7 20Y: 0.30–5.0 | µg/dL |
| Free T4 (analog-PUH) | Euthyroid: 0.89-1.76 Hypothyroid: less than 0.89 Hyperthyroid: greater than 1.78 Females Normal Range Median <i>1st Trimester:</i> 0.78-1.48 1.28 <i>2nd Trimester:</i> 0.78-1.48 1.00 <i>3rd Trimester:</i> 0.68-1.41 0.95 | ng/dL |
| T3 Uptake (SHY) | 22.5-37.0 | No units |
| Serum/Plasma | | |

| Test | Reference Range | Units |
|-------------------------------------|--|---------|
| TSH (Thyroid Stimulating Hormone) | OD: 1.0-38.9 5D: 3.0-20.0 14D: 1.7-9.1 147D: 0.8-8.2 25M: 0.7-5.7 20Y: 0.30-5.0 | µIU/mL |
| Acetaminophen | Therapeutic: 10 – 20 Hepatotoxic: 4 hours post ingestion: greater than 150 | µg/mL |
| Salicylate (SHY) | Therapeutic: 15-30 | mg/dL |
| Carbamazepine | 4.0-12.0 | µg/mL |
| Digoxin | 1.0-2.0 | ng/mL |
| Gentamicin | Peak: 6.0-10.0 Trough: 0.5-2.0 | µg/mL |
| Lithium | 0.6-1.5 | mmol/L |
| Methotrexate | None established | umol/L |
| Phenobarbital | 10.0-40.0 | µg/mL |
| Phenytoin (Dilantin) | OD: 6-14 1Y: 10-20 | µg/mL |
| Free Phenytoin | 1.0-2.0 | µg/mL |
| Tobramycin (SHY) | Peak: 6.0-10.0 Trough: 0.5-2.0 | µg/mL |
| Valproic Acid | Peak: 50-150 | µg/mL |
| Free Valproic Acid | Peak: 4.8-17.3 | ug/ml |
| Vancomycin | Trough: 10-20 | µg/mL |
| Vancomycin VNAUC 1 | >80 | ug/ml |
| Vancomycin VNAUC2 | >30 | ug/ml |
| VLDL (very low density lipoprotein) | Less than or equal to 40 | mg/dL |
| Osmolality | 281-307 | mOsm/Kg |

| Test | Reference Range | Units |
|--------------------------------------|--|-----------------|
| Cerebrospinal Fluid (CSF) Test | Reference Range | Units |
| CSF Glucose | 40-75 | mg/dL |
| CSF Lactate | 0.9-2.8 | mmol/L |
| CSF Protein | OD: 40-120 1M: 15-45 | mg/dL |
| Urine Drugs of Abuse Test | Reference Range | Units |
| Benzodiazepines (SHY) | Negative | N/A |
| Amphetamines (SHY) | Negative | N/A |
| Benzoyllecgonine (SHY) Cocaine Metab | Negative | N/A |
| Barbiturates (SHY) | Negative | N/A |
| Opiates (SHY) | Negative | N/A |
| Phencyclidine (SHY) PCP | Negative | N/A |
| 6-Acetylmorphine (SHY) | Negative | N/A |
| Buprenorphine (SHY) | Negative | N/A |
| Oxycodone (SHY) | Negative | N/A |
| Methadone (SHY) | Negative | N/A |
| Cannabinoid (SHY) THC | Negative | N/A |
| Urine Test | Reference Range | Units |
| Urine Albumin | Less than 1.9 | mg/dL |
| Albumin/Creatinine ratio | Less than 30 | mg/g creatinine |
| Urine Urea Nitrogen | 7000-160000 | mg/24 hr |
| Urine Calcium | 100-300 | mg/24 hr |
| Urine Phosphorus | 400-1300 | mg/24 hr |
| Urine Uric Acid | 250-750 | mg/24 hr |
| Urine Sodium | 40-220 | mmol/24 hr |
| Urine Potassium | 25-125 | mmol/24 hr |
| Urine Amylase | Less than or equal to 30 | IU/24 hr |
| Urine Creatinine | Female: 800-1500 1300-1800 | Male: mg/24 hr |
| Creatinine Clearance | Female: 88-128 Male: 97-137 | mL/min |
| Urine/Serum β hCG | Female: (non-pregnant) Negative Female: (pregnant) Positive Male: Negative | N/A |
| Urine Osmolality | 50-1400 | mOsm/Kg |
| Urine Total Protein | 42-225 | mg/24 hr |

| Test | Reference Range | Units |
|--------------------------|-----------------|---------|
| Urine Test | Reference Range | Units |
| Urine Color | Yellow | N/A |
| Urine Character | Clear | N/A |
| Urine Specific Gravity | 1.016 - 1.022 | N/A |
| Urine pH | 5.0 - 8.0 | N/A |
| Urine Protein | Negative | N/A |
| Urine Ketone | Negative | mg/dL |
| Urine Glucose | Negative | mg/dL |
| Urine KEtone | Negative | N/A |
| Urine Bilirubin | Negative | N/A |
| Urine Blood | Negative | N/A |
| Urine Urobilinogen | 0.0 - 1.0 | mg/dL |
| Urine Nitrite | Negative | N/A |
| Urine Leukocyte Esterase | Negative | N/A |
| Urine WBC's | 0 - 5 | Per HPF |
| Urine RBC's | 0 - 4 | Per HPF |
| Urine Epithelial Cells | 0 - 5 | Per HPF |
| Urine Bacteria | None seen | Per HPF |
| Urine Crystals | None seen | Per HPF |
| Hyaline Casts | 0-2 | Per LPF |

| Test | Reference Range | Units |
|---|---|---------|
| Blood Gas (whole Blood Specimens) | Reference Range | Units |
| pH | Arterial: 7.35-7.45 Venous: 7.32-7.43 | N/A |
| pCO ₂ (Partial pressure of carbon dioxide) | Arterial: 35-45 Venous: 41-51 | mm/Hg |
| pO ₂ (Partial pressure of oxygen) | Arterial: 80-100 Venous: 30-50 | mm/Hg |
| FO ₂ HB (Fraction of oxyhemoglobin) | Arterial: 95-99 Venous: 70-85 | % |
| iCa (Ionized Calcium) | 1.15-1.29 | mmol/L |
| Glucose (whole blood) | less than 1M: 40-99 | mg/dL |
| Sodium (whole blood) | 136-146 | mmol/L |
| Potassium (whole blood) | 3.5-5.0 | mmol/L |
| Lactate (whole blood) | 0.5-1.6 | mmol/L |
| COHb (Carboxyhemoglobin) | Non-Smokers: less than or equal to 2 Smokers: less than or equal to 10 | % |
| MetHb (Methemoglobin) | 0.0-1.5 | % |
| tHb (total hemoglobin) | Female: 12.0-16.0 Male: 13.5-17.5 | g/dL |
| HCO ₃ (Bicarbonate) | Arterial: 22-26 Venous: 19-25 | mg/L |
| Base Excess/Bass Deficient | 0 +/- 2 | N/A |
| O ₂ saturation (oxygen saturation) | Arterial: 94-99 Venous: 70-80 | % |
| a-vO ₂ (arteriovenous oxygen difference) | 4-6 | VOL% |
| O ₂ Content (oxygen content) | Arterial: 15-20 Venous: 12-17 | VOL% |
| Creatinine (whole blood) | 0.5-1.4 | mg/dL |
| Chloride (whole blood) | 98-107 | mmol/L |
| Thrombelastograph | R: 5-10 | minutes |
| | K:1-3 | minutes |
| | Angle: 53-72 | degree |
| | MA: 50-70 | mm |

Lipoprotein Reference Ranges for Adult Population (Age >=20). National Cholesterol Education Program, ATP III Classification

| | | |
|-------------------|---|-------|
| Triglyceride | Normal: less than 150 Borderline High: 150-199 High: 200-499 Very High: greater than or equal to 500 | mg/dL |
| Total Cholesterol | Desirable: less than 200 Borderline High: 200-239 High: greater than or equal to 240 | mg/dL |
| HDL | Low: less than 40 High: greater than or equal to 60 | mg/dL |

| Test | Reference Range | Units |
|------|---|-------|
| LDL | Optimal: less than 100 Near Optimal/Above Optimal: 100-129 Borderline High: 130-159 High: 160-189 Very High: Greater than or equal to 190 | mg/dL |

| Test | Reference Range | Units |
|--|---|-------|
| Pediatric (2-19 years) Lipid Reference Ranges For Cardiovascular Disease Risk | | |
| Total Cholesterol | Acceptable: Less than 170 Borderline High Risk: 170-199 High Risk: Greater than or equal to 200 | mg/dL |
| LDL Cholesterol | Acceptable: Less than 110 Borderline High Risk: 110-129 High Risk: Greater than or equal to 130 | mg/dL |
| HDL Cholesterol | Acceptable: Greater than 45 Borderline Risk: 40-45 High Risk: Less than 40 | mg/dL |
| Triglyceride | Acceptable 0D-9Y: less than 75 Acceptable 10Y-19Y: less than 90 Borderline High Risk 0D-9Y: 75-99 Borderline High Risk 10Y-19Y: 90-129 High Risk 0D-9Y: greater than or equal to 100 High Risk 10Y-19Y: greater than or equal to 130 | mg/dL |

| Test | Reference Range | Units |
|--------------------------|---|------------|
| Hematology Test | Reference Range | Units |
| Hemoglobin | Female: 11.6-14.6 Male: 12.9-16.9 | g/dL |
| Hematocrit | Female: 34.1-43.3 Male: 38.0-48.8 | % |
| WBC | 3.8-10.6 | x 10E+9/L |
| RBC | Female: 3.73-4.89 Male: 4.13-5.57 | x 10E+12/L |
| MCV | 82.6-97.4 | fL |
| MCH | 27.8-33.4 | pg |
| MCHC | 32.7-35.5 | g/dL |
| MPV | 6.8-10.4 | fL |
| RDW | 11.8-15.2 | % |
| Polys (neutrophils) | 44-77 | % |
| Bands (neutrophils) | 0-5 | % |
| Lymphs | 13-44 | % |
| Monos | 4-13 | % |
| Eos | 0-6 | % |
| Basos | 0-1 | % |
| Myelocytes | 0 | % |
| Metamyelocytes | 0 | % |
| Promyelocytes | 0 | % |
| ABS Poly | 2.24-7.68 | x 10E+09/L |
| ABS Lymphocytes | 0.80-3.65 | x 10E+09/L |
| ABS Monocytes | 0.30-0.90 | x 10E+09/L |
| ABS Eosinophils | 0.00-0.40 | x 10E+09/L |
| ABS Basophils | 0.00-0.06 | x 10E+09/L |
| ABS Bands | 0.10-0.80 | x 10E+09/L |
| ABS Myelocytes | 0 | x 10E+09/L |
| ABS Metamyelocytes | 0 | x 10E+09/L |
| ABS Promyelocytes | 0 | x 10E+09/L |
| ABS Blasts | 0 | x 10E+09/L |
| Reticulocytes | 0.4-2.4 | % |
| Absolute Reticulocytes | 0.018-0.158 | x 10E+12/L |
| Sedimentation Rate (ESR) | 18Y: Female 0-40 Male 0-23 OD: Female 0-20 Male 0-18 | mm/hr |
| Sickle Cell Screen | Negative | N/A |
| Monospot | Negative | N/A |
| Gastric Occult | Negative | N/A |
| Fluid Crystals | Negative | N/A |

| Test | Reference Range | Units |
|--|-----------------------------------|------------------|
| Synovial Fluid - Appearance | Yellow, Clear, or slightly cloudy | N/A |
| Synovial Fluid - RBC's | 0-2000 | /mm ³ |
| Synovial Fluid - Nucleated Cells | 13-180 | /mm ³ |
| Synovial Fluid - Neutrophils | 0-25 | % |
| Synovial Fluid - Lymphocytes | 0-78 | % |
| Synovial Fluid - Monocytes | 0-71 | % |
| Synovial Fluid - Mononuclear | 0-26 | % |
| Pleural - Nucleated Cells | 1395-3734 | /mm ³ |
| Pleural - Macrophages | 64-80 | % |
| Pleural - Lymphocytes | 18-36 | % |
| Pleural - Neutrophils | 0-1 | % |
| Pleural - Mesothelial | 0-2 | % |
| Peritoneal Dialysate Fluid - RBC's | 24 +/- 48 | /ul |
| Peritoneal Dialysate Fluid - Nucleated Cells | 36 +/- 48 | /ul |
| Peritoneal Dialysate Fluid - Leukocytes | 21 +/- 27 | /ul |
| Peritoneal Dialysate Fluid - Neutrophils | 18 +/- 16 | % |
| Peritoneal Dialysate Fluid - Lymphocytes | 24 +/- 26 | % |
| Peritoneal Dialysate Fluid - Monocytes | 35 +/- 26 | % |
| Peritoneal Dialysate Fluid - Eosinophils | 7 +/- 7 | % |
| Peritoneal Dialysate Fluid - Basophils | 3 +/- 2 | % |
| Cerebrospinal Fluid - Appearance | Clear | N/A |
| Cerebrospinal Fluid - Supernatant | Colorless | N/A |
| Cerebrospinal Fluid - RBC's | 0-5 | /mm ³ |
| Cerebrospinal Fluid - Nucleated Cells | 0-5 | /mm ³ |
| Cerebrospinal Fluid - Lymphocytes | 63-99 (0.63-0.99) | % |
| Cerebrospinal Fluid - Monocytes | 3-37 (0.03-0.37) | % |
| Cerebrospinal Fluid - Histiocytes | Rare | |
| Cerebrospinal Fluid - Neutrophils | 0-2 (0.00-0.02) | % |
| BAL Fluid - Alveolar macrophages | greater than 85 | % |
| BAL Fluid - Lymphocytes | 10-15 | % |
| BAL Fluid - Neutrophils | less than 3 | % |
| BAL Fluid - Eosinophils | less than 1 | % |

No Definitive Reference Ranges determined for peritoneal, amniotic and pericardial fluids

| Test | Reference Range | Units |
|---------------------------------|--|-------|
| WBC Differential Count - Poly | 1D: 32-62 1W: 28-43 1M: 19-39 6M:14-34 2Y: 12-34 6Y: 26-48 12Y: 31-61 17Y: 37-67 18Y: 44-77 | % |
| WBC Differential Count - Bands | 1D: 12-18 1W: 8-14 1M: 8-14 6M:6-12 2Y: 4-10 6Y: 2-8 12Y: 2-8 17Y: 2-8 18Y: 0-5 | % |
| WBC Differential Count - Eos | 1D: 0-3 1W: 0-3 1M: 0-3 6M: 0-3 2Y: 0-3 6Y: 0-3 12Y: 0-3 17Y: 0-3 18Y: 0-6 | % |
| WBC Differential Count - Baso | 1D: 0-2 1W: 0-2 1M: 0-2 6M:0-2 2Y: 0-2 6Y: 0-2 12Y: 0-2 17Y: 0-2 18Y: 0-1 | % |
| WBC Differential Count - Lymphs | 1D: 26-36 1W: 20-50 1M: 33-63 6M: 41-71 2Y: 45-75 6Y: 35-65 12Y: 28-48 17Y: 25-45 18Y: 13-44 | % |

| Test | Reference Range | Units |
|--------------------------------|---|--------------------|
| WBC Differential Count - Monos | 1D: 3-9 1W: 4-12 1M: 4-12 6M: 3-9 2Y: 2-8 6Y: 3-9 12Y: 3-9 17Y: 3-9 18Y: 4-13 | % |
| Reticulocyte | Newborn: 3.0-7.0 1D: 1.0-4.6 6D: 0.1-1.9 50D: 0.4-2.8 85D: 0.4-2.4 | % |
| Absolute Reticulocyte | Newborn: Unavailable 1D: Unavailable 6D: Unavailable 50D: Unavailable 85D: 0.018-0.158 | $\times 10^{12}/L$ |
| Immature Reticulocyte Fraction | 0.17-0.51 | |
| Platelet | 0D: 145-450 32D: 140-450 18Y: 156-369 | $\times 10^9/L$ |

| Test | Reference Range | Units |
|-----------------------------------|---|-------------|
| Fibrinogen | 1D: 192-374 3D: 283-401 1M: 82-383 1Y: 162-401 6Y: 199-409 11Y: 212-433 16Y: 211-518 | mg/dL |
| D-dimer | Less than 0.50 | ug/mL FEU |
| Closure Time | Collagen/ADP: 65-117 Collagen/EPI: 84-175 | Seconds |
| INR | 1D: 1.2-1.4 3D: 1.1-1.4 1M: 0.9-1.2 1Y: 0.9-1.2 6Y: 0.9-1.2 11Y: 1.0-1.3 16Y: 0.8- 1.2 | N/A |
| Prothrombin Time (PT) | 1D: 14.4-16.4 3D: 13.5-16.4 1M: 11.5-15.3 1Y: 12.1-14.5 6Y: 11.7-15.1 11Y: 12.7-16.1 16Y: 11.9-14.5 | Seconds |
| Partial Thromboplastin Time (PTT) | 1D: 34.3-44.8 3D: 29.5-42.2 1M: 35.1-46.3 1Y: 33.6-43.8 6Y: 31.8-43.7 11Y: 33.9-46.1 16Y: 22.6-34.3 | Seconds |
| Thrombin Time (SHY) | 14.5-18.4 | Seconds |
| Aspirin Response | Non-therapeutic baseline: 550-700 Therapeutic response to aspirin: 350-549 | ARU |
| Plavix Response | Normal Baseline range: 194-418 | Base PRU |
| LMW Heparin | Call Pharmacy | I μ /mL |
| UF Heparin | Call Pharmacy | I μ /mL |
| Acetone | Negative | |
| Kleihauer Betke Fetal HGB | Less than 0.04 | % |
| Kleihauer Betke Fetal Bleed | Less than 2.00 | mL |
| Fetal APT Test | Negative | |

| Test | Reference Range | Units |
|------------------------|---|-----------------------|
| White Blood Cell (WBC) | 1D: 9.0-38.0 1W: 5.0-21.0 2W: 5.0-20.0 4W: 5.0-19.5 2M: 6.0-17.5 3M: 6.0-17.5 6M: 6.0-17.5 2Y: 5.0-17.0 6Y: 4.5-14.5 12Y: 4.5-13.0 18Y: 3.8-10.6 | x 10 ⁹ /L |
| Hemoglobin (HGB) | 1D: 13.5-21.0 1W: 13.5-21.0 2W: 12.5-20.2 4W: 10.0-18.0 2M: 9.0-14.0 3M: 9.5-13.5 6M: 10.5-13.5 2Y: 11.5-13.5 6Y: 11.5-15.5 12Y: Female-12.0-16.0 Male-13.5-17.5 18Y: Female-11.6-14.6 Male-12.9-16.9 | g/dL |
| Hematocrit (HCT) | 1D: 42.0-60.0 1W: 42.0-66.0 2W: 39.0-63.0 4W: 31.0-55.0 2M: 28.0-42.0 3M: 29.0-41.0 6M: 33.0-39.0 2Y: 34.0-40.0 6Y: 35.0-45.0 12Y: Female-36.0-46.0 Male-37.0-49.0 18Y: Female-34.1-43.3 Male-38.0-48.8 | % |
| Red Blood Cell (RBC) | 1D: 3.9-6.60 1W: 3.90-6.30 2W: 3.60-6.20 4W: 3.00-5.40 2M: 2.70-4.90 3M: 3.10-4.50 6M: 3.70-5.30 2Y: 3.90-5.30 6Y: 4.00-5.20 12Y: Female-4.10-5.20 Male-4.50-5.30 18Y: Female-3.73-4.89 Male-4.13-5.57 | x 10 ¹² /L |

| Test | Reference Range | Units |
|--|--|-------|
| Mean Corpuscular Volume (MCV) | 1D: 98-118 1W: 88-126 2W: 86-124 4W: 85-123 2M: 77-115 3M: 74-108 6M: 70-86 2Y: 75-87 6Y: 77-95 12Y: 78-102 18Y: 82.6-97.4 | fL |
| Mean Corpuscular Hemaglobin (MCH) | 1D: 35-39 1W: 33-41 2W: 31-39 4W: 29-35 2M: 29-35 3M: 27-33 6M: 27-33 2Y: 25-31 6Y: 24-30 12Y: 38-32 18Y: 37.8-33.4 | pg |
| Mean Corpuscular Hemaglobin Conc. (MCHC) | 1D: 32-35 1W: 31-35 2W: 31-35 4W: 31-35 2M: 31-35 3M: 31-35 6M: 31-35 2Y: 31-35 6Y: 31-35 12Y: 31-36 18Y: 32.7-35.5 | g/dL |